Reimbursement Options in Canada

TAKHZYRO® (lanadelumab injection) is indicated for routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults. TAKHZYRO is not intended for acute treatment of HAE attacks.

Both public and private reimbursement options for adult patients

Choose your province for coverage criteria

Canada map
OnePath
OnePath subimg

Reimbursement questions?

Contact the OnePath® Patient Support Program for assistance.

Phone: 1‑844‑MY1‑PATH (1‑844‑691‑7284)
Monday through Friday, 8 a.m. to 8 p.m. EST
Fax: 1‑844‑951‑7284
Email: support@onepathprogram.ca

Consult the product monograph at www.takeda.com/en-ca/takhzyropm for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling 1-800-268-2772.

  • Each province and territory has specific coverage criteria. Contact OnePath® for more details concerning the reimbursement process.